Zydus Lifesciences reports lower net profit in second quarter despite higher revenue

Zydus Lifesciences reported a 26.6 per cent drop in its consolidated net profit to ₹925.5 crore for the September quarter. The company posted a net profit of ₹1,260.9 crore in the same period of the previous fiscal year. Higher expenses caused the profit decline, moving up sharply to ₹6,806.6 crore from ₹4,509 crore in the year-ago period. Revenue from operations rose to ₹7,909.6 crore during the quarter from ₹6,123.2 crore a year earlier. The pharma business made up 83 per cent of total sales. India formulations brought in ₹1,884.4 crore, marking an 18 per cent year-on-year rise. North America formulations generated ₹3,314.5 crore, up 21 per cent, driven by volume growth and US specialty business expansion. Managing Director Sharvil Patel noted steady growth across branded businesses in India, international markets, and wellness, with branded sales in the US reaching 16 per cent. Patel also pointed to the upcoming approval and launch of Saroglitazar in the US. During the April-September period of the fiscal year, net profit fell 30.86 per cent to ₹1,885.9 crore from ₹2,727.7 crore. Shares of the company traded 3.35 per cent lower at ₹1,197.50 apiece on the BSE at 1:25 pm.

Context

Pharmaceutical companies often experience rising expenses alongside revenue growth when they invest in new markets, specialty products, and research and development. Quarterly financial results help investors track how well a firm balances its operational costs with incoming sales from different global regions.